Study 20 of 39 for search of: "Beta-Thalassemia"
Previous Study Return to Search Results Next Study

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Phase II Study of Azacitidine and Phenylbutyrate in Patients With Thalassemia Major
This study has been terminated.
Sponsored by: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Information provided by: Office of Rare Diseases (ORD)
ClinicalTrials.gov Identifier: NCT00007072
  Purpose

OBJECTIVES:

I. Determine the safety and efficacy of azacitidine and phenylbutyrate in treatment of patients with thalassemia major.


Condition Intervention Phase
Thalassemia Major
Drug: azacitidine
Drug: phenylbutyrate
Phase II

Genetics Home Reference related topics: beta thalassemia
MedlinePlus related topics: Thalassemia
Drug Information available for: Azacitidine Sodium phenylbutyrate
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment

Further study details as provided by Office of Rare Diseases (ORD):

Estimated Enrollment: 24
Study Start Date: November 2000
Detailed Description:

PROTOCOL OUTLINE: Patients receive azacitidine IV continuously on days 1-4 and oral phenylbutyrate three times a day on days 14-42. Bone marrow needle aspiration is performed on days 6, 14, and 42 to assess disease response to treatment. If no response on day 42, a second course of azacitidine and phenylbutyrate begins 7 days later.

Patients are followed weekly for 3 months and then monthly thereafter.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

PROTOCOL ENTRY CRITERIA:

--Disease Characteristics--

Diagnosis of thalassemia major Progressive disease defined as: Increasing transfusion requirement or difficulty in maintenance of hemoglobin levels greater than 7 g/dL as a consequence of autologous or allogeneic antibodies OR Increasing extramedullary hematopoiesis causing compression phenomena OR Disease with complications of iron overload despite traditional transfusion and iron chelation therapy (e.g., heart failure, decreased cardiac ejection fraction, endocrinopathy, or evidence of progressive liver dysfunction)

Standard transfusion therapy or iron chelation therapy must be contraindicated

--Prior/Concurrent Therapy--

See Disease Characteristics

--Patient Characteristics--

Performance status: ECOG 0-2

Life expectancy: Greater than 10 days Not moribund

Hematopoietic: See Disease Characteristics

Hepatic: See Disease Characteristics AST or ALT no greater than 3 times upper limit of normal (ULN) Bilirubin no greater than 1.5 times ULN (unless due to hemolysis or Gilbert's disease) Albumin at least 3 g/dL No severe concurrent hepatic disease

Renal: Creatinine no greater than 2 mg/dL Creatinine clearance at least 60 mL/min No severe concurrent renal disease

Cardiovascular: See Disease Characteristics No New York Heart Association class III or IV

Other: Not pregnant or nursing No severe concurrent metabolic disease No severe sepsis or septic shock No concurrent altered mental status or seizure disorder No concurrent myelodysplastic syndrome or leukemia

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00007072

Locations
United States, Maryland
Clinical Hematology Branch
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
Investigators
Study Chair: Griffin Platt Rodgers National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  More Information

Study ID Numbers: 199/15578, NIDDK-00-DK-0166, NCI-1311
Study First Received: December 6, 2000
Last Updated: June 23, 2005
ClinicalTrials.gov Identifier: NCT00007072  
Health Authority: United States: Federal Government

Keywords provided by Office of Rare Diseases (ORD):
genetic diseases and dysmorphic syndromes
hematologic disorders
rare disease
thalassemia major

Study placed in the following topic categories:
4-phenylbutyric acid
Hematologic Diseases
Beta-thalassemia
Rare Diseases
Anemia
Anemia, Hemolytic
Thalassemia
Anemia, Hemolytic, Congenital
Thalassemia minor
Genetic Diseases, Inborn
Beta-Thalassemia
Hemoglobinopathies
Azacitidine
Hemoglobinopathy

Additional relevant MeSH terms:
Antimetabolites
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Therapeutic Uses
Enzyme Inhibitors
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009